Dublin, Nov. 28, 2017 -- The "Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021" report has been added to Research and Markets' offering.
The global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.
The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors. The report also includes a discussion of the key vendors operating in this market.
According to the report, one of the major drivers for this market is Rising R&D expenditure in pharmaceutical and biotechnology sectors. The pharmaceutical industry is witnessing a global surge in research funding to combat various rare diseases developing globally or to explore new therapies for existing conditions. The pharmaceutical R&D spending is expected to increase by 4% between 2016 to 2022. Biotechnology companies are also making increased investments in R&D. The US was the largest investor in biotechnology R&D in 2015 investing around $28 billion. France was the second largest investor in biotechnology R&D in 2015 investing over $3.6 billion, followed by Switzerland investing over $2.8 billion. South Korea was the largest investor in biotechnology R&D in Asia, investing over $1.7 billion.
The latest trend gaining momentum in the market is Increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth. Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells. Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.
Further, the report states that one of the major factors hindering the growth of this market is Challenges in development of nanoparticles for therapeutics. Although nanoparticle-based therapeutics overcome biological barriers by effectively delivering hydrophobic drugs at preferentially target sites of disease, only a small number of nanoparticle-based medicines have been approved for clinical use. Manufacturers of nanoparticles face numerous challenges and hurdles at different stages of product development. The complexity of nanoparticles requires careful design and engineering for their three-dimensional construction. Their development requires detailed analysis of orthogonal methods, pharmacological profiles, and biological behaviors. Nanoparticles require detailed characterization and the successful manufacture of these complex constructs.
Key vendors
- F. Hoffmann-La Roche
- GE Healthcare
- Merck
- Novartis
Other prominent vendors
- AMAG Pharmaceuticals
- Amgen
- Bausch & Lomb
- Biogen
- Celgene
- Gilead
- Ipsen
- Leadiant Biosciences
- nanoComposix
- Pacira Pharmaceuticals
- Pfizer
- Shire
- UCB
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Market outline
PART 05: MARKET LANDSCAPE
- Market size and forecast
- Five forces analysis
PART 06: MARKET SEGMENTATION BY END-USER
- Comparison by end-user
- Biotechnology
- Pharmaceutical
- Market opportunity by end-user
PART 07: REGIONAL LANDSCAPE
- Regional comparison
- Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
- Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
- Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
- Market opportunity
PART 08: DECISION FRAMEWORK
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
- Increasing demand for nanoparticles in stem cell therapy
- Increasing prevalence of chronic diseases
- Increasing use of gold nanoparticles
PART 11: VENDOR LANDSCAPE
- Competitive scenario
- Investment opportunity
PART 12: VENDOR ANALYSIS
- Vendor overview
- Merck
- F. Hoffmann-La Roche
- GE Healthcare
- Novartis
- Other prominent vendors
PART 13: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/457rxf/global
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Nanotechnology, Nanomedicine , Nanomaterials


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Anta Sports Expands Global Footprint With Strategic Puma Stake
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



